Women's Cancer Study Group GmbH: Phase 3 study closed enrollment, 1684 enrolled (Breast Cancer Female)
Women's Cancer Study Group GmbH: Phase 3 study closed enrollment, 1684 enrolled (Breast Cancer Female). Its enrollment of 1,684 is top-decile (96th percentile of 8,879 records). Dated 27 days ago, it is in the active follow-up window. Score 55/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 1,684 · 96th percentile of 8,879 ClinicalTrialStartPulse records · 21.1x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Women's Cancer Study Group GmbH |
| Sponsor type | Academic and hospital |
| Study | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
| NCT ID | NCT04055493 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Breast Cancer Female |
| Intervention types | drug |
| Target enrollment | 1684 |
| Site countries | Germany |
| Posted | 2019-08-13 |
| Planned start | 2019-07-02 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-09 |
| enrollment percentile | 96th of 8,879 (median 80, 21.1x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Women's Cancer Study Group GmbH
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Women's Cancer Study Group GmbH + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-09
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Women's Cancer Study Group GmbH and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Women's Cancer Study Group GmbH's enrollment: 96th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
55 / 100 Score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1684 participants planned.
What is the ClinicalTrialStartPulse record for Women's Cancer Study Group GmbH?
Women's Cancer Study Group GmbH's Phase 3 study (NCT04055493) in Breast Cancer Female, first posted 2019-08-13: enrollment closed (active, not recruiting) (2026-10-09), in an update posted 2026-10-09.
How does Women's Cancer Study Group GmbH compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 1,684 is 21.1x the median of 80 across 8,879 records. It is 27 days old, still within a typical 45-day follow-up window.
Women's Cancer Study Group GmbH vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Women's Cancer Study Group GmbH | NONUS | 1,684 | 96th | 2026-10-09 |
| Merck Sharp & Dohme LLC | US | 1,104 | 95th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 864 | 93rd | 2026-11-03 |
| Janssen Research & Development, LLC | US | 743 | 92nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Women's Cancer Study Group GmbH and peer phase 3 records
Get new ClinicalTrialStartPulse records like Women's Cancer Study Group GmbH by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.